WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 6, 1652-1658. Review Article ISSN 2277–7105

NANOMATERIALS IN MALARIA CONTROL IN AFRICA: ADVANCED MECHANISMS, APPLICATIONS, AND FUTURE PERSPECTIVES

Mohammed Sulieman Ali Eltoum[1,2,*], Isaac Ayii Ayii[1]

[1]Ayii University, School of Pharmacy, Juba, South Sudan.

[2]University of Juba, School of Pharmacy Juba, South Sudan.

Article Received on 15 February 2026,
Article Revised on 05 March 2026,
Article Published on 16 April 2026,

https://doi.org/10.5281/zenodo.19087142

***Corresponding Author**

Mohammed Sulieman Ali Eltoum

Ayii University, School of Pharmacy, Juba, South Sudan.

How to cite this Article: Mohammed Sulieman Ali Eltoum[1,2,*], Isaac Ayii Ayii[1]. (2026). Nanomaterials In Malaria Control In Africa: Advanced Mechanisms, Applications, and Future Perspectives. World Journal of Pharmaceutical Research, 15(6), 1652–1658.

ABSTRACT

Malaria remains one of the most devastating infectious diseases in Sub Saharan Africa, accounting for nearly 95% of global malaria morbidity and mortality.[1] Despite progress in artemisinin based combination therapies (ACTs), insecticide treated nets (ITNs), and rapid diagnostic tests (RDTs), challenges such as drug resistance, vector resistance, poor drug bioavailability, and limited early diagnostic sensitivity persist. Nanotechnology, involving the engineering of materials at the nanoscale (1–100 nm), provides promising tools to address these limitations. Nanomaterials exhibit unique physicochemical properties including high surface area, tunable surface chemistry, and enhanced permeability that enable targeted drug delivery, controlled drug release, ultrasensitive diagnostics, and eco-friendly vector control strategies. This review summarizes recent advances in the use of nanomaterials for malaria therapy, diagnosis, and prevention with emphasis on the African context. Mechanistic aspects of nanocarrier pharmacokinetics, blood–brain barrier transport, green synthesis approaches, toxicological considerations, and regulatory frameworks are also discussed. The integration of nanomedicine with malaria control programs may significantly enhance disease management and contribute to global malaria elimination efforts.[2]

KEYWORDS: Nanomaterials, Malaria, infectious diseases, nanocarrier pharmacokinetics, Plasmodium, artemisinin.

1. INTRODUCTION

Malaria is a life threatening parasitic disease caused by protozoa of the genus Plasmodium and transmitted through bites of infected female Anopheles mosquitoes. Sub Saharan Africa bears the highest global burden of malaria infections and mortality. Children under five years of age and pregnant women remain the most vulnerable populations. Although artemisinin based combination therapies have improved treatment outcomes, the emergence of parasite resistance and insecticide resistant mosquito vectors threatens progress toward malaria elimination. Innovative technological strategies are therefore required to enhance existing control methods. Nanotechnology has emerged as a multidisciplinary approach capable of improving therapeutic delivery, diagnostic sensitivity, and vector control efficiency.[1]

Table 1: Estimated Malaria Burden in Africa (WHO Data).

Indicator	Global Estimate	Africa Contribution (%)
Annual Cases	»249 million	94–95%
Annual Deaths	»608,000	»95%
Deaths in Children	<5 Majority	>75% in Africa

2. Physicochemical Properties of Nanomaterials

Nanomaterials possess distinctive characteristics due to their nanoscale size including large surface - to - volume ratio, enhanced chemical reactivity, and tunable surface functionalization. These properties allow nanomaterials to interact effectively with biological systems. Common nanomaterials investigated in malaria research include liposomes, polymeric nanoparticles (PLGA and chitosan), metallic nanoparticles such as gold and silver, magnetic nanoparticles, dendrimers, and solid lipid nanoparticles. These systems can be engineered to encapsulate antimalarial drugs, improve solubility, and facilitate targeted delivery to infected cells.[3]

3. Nanocarrier Based Drug Delivery

Nanocarriers have the ability to improve therapeutic outcomes by enhancing drug bioavailability and reducing systemic toxicity. Polymeric nanoparticles such as PLGA provide controlled drug release through hydrolytic degradation. Liposomes can encapsulate both hydrophilic and hydrophobic drugs while protecting them from metabolic degradation. Targeted nanocarriers can also be functionalized with antibodies or ligands that recognize receptors on infected erythrocytes, enabling selective drug delivery to malaria parasites.[4]

4. Mechanistic Basis of Nanocarrier Drug Delivery

Nanocarriers improve therapeutic index through enhanced permeability and retention.[5] (EPR) effects, receptor-mediated endocytosis, and controlled degradation kinetics. Polymeric nanoparticles such as PLGA undergo hydrolytic cleavage, allowing sustained Release.[6] Liposomes mimic biological membranes and reduce first-pass metabolism.[4] Surface functionalization with antibodies enables targeting of infected erythrocytes.

5. Pharmacokinetics and Controlled Drug Release

Nanocarrier systems modify drug pharmacokinetics by prolonging circulation time and maintaining stable therapeutic concentrations. Controlled release from nanoparticles prevents rapid fluctuations in drug levels and reduces the risk of sub therapeutic exposure, which is a major contributor to antimalarial drug resistance.[7]

A primary pharmacological challenge in Africa is the short half-life of conventional drugs, leading to missed doses and sub-therapeutic levels that fuel resistance.

Table 2: Nanocarrier,mechanism of action and key advantages.

Nanocarrier Type	Mechanism of Action	Key Advantages
Liposomes	Phospholipid bilayers encapsulating drugs.	Biocompatible; reduces first-pass metabolism.
Polymeric NPs	Biodegradable polymers (e.g., PLGA).	Sustained release; ideal for preventive treatment.
Dendrimers	Highly branched macromolecules.	High drug loading and precise targeting.
Solid Lipid NPs	Lipid-based matrix.	Can cross the blood-brain barrier for cerebral malaria.

6. Controlled Drug Release Kinetics

Sustained drug release reduces sub-therapeutic exposure and delays resistance development. Nanocarriers demonstrate prolonged plasma half-life compared to free drugs, as illustrated in Figure 1.



Figure 1. Drug Release Kinetics: Free Drug vs Nanocarrier.

7. Blood–Brain Barrier Transport in Cerebral Malaria[8]

Cerebral malaria represents one of the most severe complications of Plasmodium falciparum infection. Nanoparticles such as solid lipid nanoparticles and surface - modified polymeric nanoparticles can cross the blood–brain barrier via receptor - mediated transcytosis and other mechanisms. These delivery systems offer promising strategies for improving treatment of severe malaria. Cerebral malaria requires therapeutic penetration across the blood–brain barrier (BBB). Functionalized nanoparticles achieve superior BBB transport efficiency via receptor-mediated transcytosis.[1]



Figure 2. BBB Transport Efficiency of Various Delivery Systems.

8. Nanotechnology in Malaria Diagnosis

Nanotechnology has enabled the development of highly sensitive diagnostic systems. Gold nanoparticle biosensors can detect malaria biomarkers such as histidine rich protein II and Plasmodium lactate dehydrogenase. Quantum dots provide strong fluorescence and photostability, allowing multiplex detection of parasite antigens. Magnetic nanoparticles can also concentrate parasites by targeting hemozoin crystals, improving diagnostic accuracy in low parasitemia infections. In many rural African settings, "blind treatment" of fevers occurs because current diagnostic tools are often insufficiently sensitive to detect low parasite densities.[1]

- **Gold Nanoparticles (AuNPs):** When functionalized with monoclonal antibodies, AuNPs significantly enhance the detection of biomarkers such as Histidine-Rich Protein II (HRP2).
- **Quantum Dots (QDs):** These semiconductor nanocrystals offer superior fluorescence stability (no photobleaching) and multiplexing capacity, allowing for detection levels far below standard Rapid Diagnostic Tests (RDTs).[9]

- **Magnetic Nanoparticles (MNPs):** MNPs exploit the paramagnetic properties of hemozoin (a byproduct of hemoglobin digestion by the parasite) to "pull" infected cells out of a blood sample, improving microscopy accuracy for low-grade infections.[10]



Figure 3. Comparative Sensitivity of Diagnostic Techniques.

9. Green Nanotechnology for Vector Control

Green synthesis methods utilize plant extracts such as Moringa oleifera and Azadirachta indica to produce nanoparticles in an environmentally friendly manner. These plant derived nanoparticles exhibit larvicidal activity against Anopheles mosquitoes and may provide sustainable vector control strategies suitable for low resource regions.[11]

Conventional insecticide-treated nets (ITNs) often lose potency due to washing and heat.

- **Nano-insecticides:** Micro-encapsulation allows for a slow release of poison over 3–5 years, ensuring nets remain lethal to mosquitoes for their entire lifespan.
- **Green Synthesis:** Utilizing indigenous African flora like *Moringa oleifera* and *Azadirachta indica* (Neem), researchers can produce metallic nanoparticles in an eco-friendly and cost-effective manner. These plant-mediated nanoparticles demonstrate potent larvicidal activity against *Anopheles* larvae.[11]

10. Toxicological Considerations

Despite their advantages, nanomaterials may present potential safety risks including oxidative stress, tissue accumulation, and environmental persistence. Comprehensive toxicological studies are therefore required to evaluate long term safety before large scale implementation.[12]

11. Regulatory Challenges in Africa

Implementation of nanomedicine in malaria control requires appropriate regulatory frameworks. The African Medicines Agency(AMA) and national regulatory bodies play critical roles in establishing guidelines for evaluation, approval, and monitoring of nanotechnology based therapeutics and diagnostics.[13]

The transition from lab to clinic in Africa faces several hurdles

- **Manufacturing:** Most African nations lack the "Clean Room" facilities required for high-volume nano-manufacturing.
- **Nano-Toxicology:** There is a critical need to study how nanoparticles behave in the human body over long periods, particularly in populations with high rates of malnutrition or co-infections like HIV.
- **Regulation:** African regulatory bodies, such as the emerging African Medicines Agency (AMA), must develop specific guidelines for "Nano-similars" to ensure safety and quality control.[13]

12. CONCLUSION

Nanotechnology offers transformative opportunities for malaria control through improved drug delivery systems, advanced diagnostic tools, and sustainable vector control approaches. Continued interdisciplinary research, increased funding, and regulatory development will be essential to translate nanotechnology innovations into practical public health solutions in Africa. Also Nanotechnology is a critical tool for the eradication of malaria in Africa. By combining indigenous knowledge (Green Synthesis) with cutting-edge engineering (Targeted Delivery), the continent can move from being a consumer of foreign medicine to a producer of high-tech health solutions. However, infrastructure development and regulatory harmonization remain essential to realize this potential.

ACKNOWLEDGEMENT

the cross ponding author would like to thank Ayii University for the financial support and encouraging the scientific publishing.

REFERENCES

1. World Health Organization. World Malaria Report. WHO Press.
2. Whitesides GM. The origins and future of nanotechnology. Nature.
3. Nel A et al. Understanding biophysicochemical interactions at the nano–bio interface.

Nature Materials.

4. Torchilin VP. Liposomes in drug delivery. Nature Reviews Drug Discovery.
5. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews.
6. Mhlwatika Z, Aderibigbe BA. Polymeric nanocarriers for the delivery of antimalarials. Molecules.
7. Alexis F et al. Factors affecting the clearance of nanoparticles. Molecular Pharmaceutics.
8. Jain S et al. Nanotechnology for malaria diagnosis and treatment. Nanomedicine.
9. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clinica Chimica Acta.
10. Magnetic nanoparticle-based diagnostics for infectious diseases. Biosensors and Bioelectronics.
11. Green synthesis of nanoparticles for vector control. Environmental Nanotechnology.
12. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer.
13. African Medicines Agency framework documents.